

Maurizio Sessa  
Lektor  
Farmaceutisk Informatik  
**Postadresse:**  
Universitetsparken 2  
2100  
København Ø  
**E-mail:** Maurizio.sessa@sund.ku.dk  
**Telefon:** +4535337831  
**Hjemmeside:** <https://ilf.ku.dk/>



## Kort præsentation

Older adults are the main consumers of drugs but are rarely included in pivotal randomized clinical trials. Hence, post-marketing surveillance is a pivotal activity to better characterize the safety and effectiveness of medications in older patients.

I am currently coordinating a team integrating multidisciplinary expertise from Pharmacoepidemiology, Pharmacovigilance, and Data science to catalyze the identification of subgroups of older patients at higher risk of adverse drug reactions or not sufficiently benefitting from pharmacological treatments using post-marketing data sources (e.g., administrative and spontaneous reporting databases). The team has a strong translational perspective as its final goal is to promote the integration of discoveries into patient care.

The team has access to the biggest cohort of older individuals in Denmark covering the entire Danish population aged  $\geq 65$  for which they have socio-demographic information, hospital- and ambulatory access to Danish hospitals, pharmacological and non-pharmacological treatments, laboratory results (i.e., biochemical, genetic, and immunological), surgery, and procedures.

## Kvalifikationer

Regulatory affairs, Certified program in EU Regulatory Affairs  
Dimissionsdato: 1 sep. 2017

Translational pharmacology, PhD  
Dimissionsdato: 20 dec. 2016

## Ansættelse

### Lektor

Farmaceutisk Informatik  
Københavns Universitet  
København Ø  
1 maj 2018 → nu

### Tenure track adjunkt

LUKKET: Pharmacotherapy  
Københavns Universitet  
København Ø, Danmark  
1 sep. 2019 → 3 jan. 2020

## Publikationer

### Artificial intelligence for the optimal management of community-acquired pneumonia

Barbieri, M. A., Battini, V. & Sessa, Maurizio, 2024, I: Current Opinion in Pulmonary Medicine. 30, 3, s. 252-257

### Comparing major and mild cognitive impairment risks in older type-2 diabetic patients: a Danish register-based study on dipeptidyl peptidase-4 inhibitors vs. glucagon-like peptide-1 analogues

Battini, V., Barbieri, M. A., Carnovale, C., Spina, E., Clementi, E. & Sessa, Maurizio, 2024, (E-pub ahead of print) I: Journal of Neurology.

### Drug Repurposing in Crohn's Disease Using Danish Real-World Data

Shakibfar, Saeed, Allin, K. H., Jess, T., Barbieri, M. A., Battini, V., Simoncic, E., Kirchgesner, J., Ulven, Trond & Sessa, Maurizio, 2024, I: Pragmatic and observational research. 15, s. 17-29

**Exploring the impact of co-exposure timing on drug-drug interactions in signal detection through spontaneous reporting system databases: a scoping review**

Cocco, M., Carnovale, C., Clementi, E., Barbieri, M. A., Battini, V. & Sessa, Maurizio, 2024, (E-pub ahead of print) I: Expert Review of Clinical Pharmacology.

**Impact of the early COVID-19 pandemic on adult mental health-related dispensed medications, hospitalizations and specialist outpatient visits in Norway and Sweden: Interrupted time series analysis**

Moreno-Martos, D., Zhao, J., Li, H., Nyberg, F., Bjørndal, L. D., Hajiebrahimi, M., Wettermark, B., Aakjær, Mia, Andersen, Morten, Sessa, Maurizio, Lupattelli, A., Nordeng, H. & Morales, D. R., 2024, (E-pub ahead of print) I: British Journal of Clinical Pharmacology.

**Optimizing Signal Management in a Vaccine Adverse Event Reporting System: A Proof-of-Concept with COVID-19 Vaccines Using Signs, Symptoms, and Natural Language Processing**

Dong, G., Bate, A., Haguinet, F., Westman, G., Dürlich, L., Hviid, Anders Peter & Sessa, Maurizio, 2024, I: Drug Safety. 47, s. 173-182

**Persistence and adherence with Latanoprost: A Danish register-based cohort study in older patients with glaucoma**

Amiri, D., Sessa, Maurizio, Andersen, Morten & Kolko, Miriam, 2024, I: Acta Ophthalmologica. 102, 2, s. 172-178 7 s.

**Ticagrelor or prasugrel vs. clopidogrel in patients with atrial fibrillation undergoing percutaneous coronary intervention for myocardial infarction**

Godtfredsen, S. J., Kragholm, K. H., Kristensen, A. M. D., Bekfani, T., Sørensen, Rikke, Sessa, Maurizio, Torp-Pedersen, Christian, Bhatt, D. L. & Pareek, M., 2024, I: European Heart Journal Open. 4, 1, 9 s., oead134.

**Timing Matters: A Machine Learning Method for the Prioritization of Drug-Drug Interactions Through Signal Detection in the FDA Adverse Event Reporting System and Their Relationship with Time of Co-exposure**

Battini, V., Cocco, M., Barbieri, M. A., Powell, G., Carnovale, C., Clementi, E., Bate, A. & Sessa, Maurizio, 2024, (E-pub ahead of print) I: Drug Safety.

**A novel approach for pharmacological substantiation of safety signals using plasma concentrations of medication and administrative/healthcare databases: a case study using Danish registries for an FDA warning on lamotrigine**

Wang, W., Battini, V., Carnovale, C., Noordam, R., van Dijk, K. W., Kragholm, K. H., van Heemst, D., Soeorg, H. & Sessa, Maurizio, 2023, I: Pharmacological Research. 193, 8 s., 106811.

**Artificial intelligence-based disease risk score for community-acquired pneumonia hospitalization in older individuals: a Danish register-based study**

Shakibfar, Saeed, Andersen, Morten & Sessa, Maurizio, 2023, I: iScience. 26, 7, 16 s., 107027.

**Artificial intelligence-driven prediction of COVID-19-related hospitalization and death: a systematic review**

Shakibfar, Saeed, Nyberg, F., Li, H., Zhao, J., Nordeng, H. M. E., Sandve, G. K. F., Pavlovic, M., Hajiebrahimi, M., Andersen, Morten & Sessa, Maurizio, 2023, I: Frontiers in Public Health. 11, 15 s., 1183725.

**Developing an Artificial Intelligence-Guided Signal Detection in the Food and Drug Administration Adverse Event Reporting System (FAERS): A Proof-of-Concept Study Using Galcanezumab and Simulated Data**

Al-Azzawi, F., Mahmoud, I., Haguinet, F., Bate, A. & Sessa, Maurizio, 2023, I: Drug Safety. 46, s. 743-751

**Machine learning-driven development of a disease risk score for COVID-19 hospitalization and mortality: a Swedish and Norwegian register-based study**

Shakibfar, Saeed, Zhao, J., Li, H., Nordeng, H., Lupattelli, A., Pavlovic, M., Sandve, G. K., Nyberg, F., Wettermark, B., Hajiebrahimi, M., Andersen, Morten & Sessa, Maurizio, 2023, I: Frontiers in Public Health. 11, 16 s., :1258840.

**Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines**

Pareek, M., Sessa, P., Polverino, P., Sessa, F., Kragholm, K. H. & Sessa, Maurizio, 2023, I: Frontiers in Cardiovascular Medicine. 10, 9 s., 1210007.

**One-year incidence of depression, anxiety, or stress disorders following a first-time heart failure diagnosis: A Danish nationwide registry-based study**

Pedersen, M. W., Rørth, R., Andersen, M. P., Sessa, Maurizio, Polcwiartek, C., Riddersholm, S. J., Gislason, Gunnar Hilmar, Kristensen, S. L., Andersen, N. H., Køber, Lars Valeur, Søgaaard, P., Torp-Pedersen, C. & Kragholm, K. H., 2023, I: American Heart Journal Plus: Cardiology Research and Practice. 25, 6 s., 100240.

**Trends in Medical and Device Therapies Following Incident Heart Failure in Denmark during 1996–2019: A Nationwide Register-Based Follow-Up Study**

Ettrup-Christensen, A., Butt, J. H., Andersen, M. P., Sessa, Maurizio, Polcwiartek, C., Fosbøl, E. L., Rørth, R., Kristensen, S. L., Torp-Pedersen, Christian, Køber, Lars Valeur, Schou, Morten, Tayal, B., Søgaaard, P. & Kragholm, K., 2023, I: Journal of Cardiovascular Development and Disease. 10, 9, 10 s., 362.

**Ubrogепant and rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies**

Dong, G., Kjærgaard, N. A., Shakibfar, Saeed & Sessa, Maurizio, 2023, I: Expert Opinion on Drug Safety. 22, 1, s. 59-70

**Ubrogепant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System**

Battini, V., Carnovale, C., Clementi, E. & Sessa, Maurizio, 2023, I: Expert Opinion on Drug Safety. 22, 11, s. 1105-1112

**Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study**

Meaidi, A., Mascolo, A., Sessa, Maurizio, ktl594, ktl594, Skals, R., Gerds, Thomas Alexander, Wessel Skovlund, C., Mørch, L. S., Rossi, F., Capuano, A., Lidegaard, Øjvind & Torp-Pedersen, Christian, 2023, I: BMJ (Clinical research ed.). 382, 10 s., e074450.

**A machine-learning guided method for predicting add-on and switch in secondary data sources: A case study on anti-seizure medications in Danish registries**

Breitenstein, P. S., Mahmoud, I., Al-Azzawi, F., Shakibfar, Saeed & Sessa, Maurizio, 2022, I: Frontiers in Pharmacology. 13, 11 s., 954393.

**Artificial neural network vs pharmacometric model for population prediction of plasma concentration in real-world data: a case study on valproic acid**

Soeorg, H., Sverrisdóttir, E., Andersen, Morten, Lund, Trine Meldgaard & Sessa, Maurizio, 2022, I: Clinical Pharmacology and Therapeutics. 111, 6, s. 1278-1285

**Comparison of the incidence of acute pancreatitis among new users of fluoxetine, citalopram, and other selective serotonin reuptake inhibitors: A Danish register-based cohort study**

Aakjær, Mia, Kristiansen, S. B., Sessa, Maurizio, Pape, K., Dalhoff, Kim, De Bruin, M. L. & Andersen, Morten, 2022, I: Pharmacoepidemiology and Drug Safety. 31, S2, s. 641-642

**Effectiveness and safety of P2Y<sub>12</sub> inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study**

Godtfredsen, S. J., Kragholm, K. H., Leutscher, P., Jørgensen, S. H., Christensen, M. K., Butt, J. H., Gislason, Gunnar Hilmar, Køber, Lars Valeur, Fosbøl, Emil Loldrup, Sessa, Maurizio, Bhatt, D. L., Torp-Pedersen, Christian & Pareek, M., 2022, I: European Heart Journal: Acute Cardiovascular Care. 11, 9, s. 697–705

**Hypothermic oxygenated perfusion in extended criteria donor liver transplantation: A randomized clinical trial**

Ravaioli, M., Germinario, G., Dajti, G., Sessa, Maurizio, Vasuri, F., Siniscalchi, A., Morelli, M. C., Serenari, M., Del Gaudio, M., Zanfi, C., Odaldi, F., Bertuzzo, V. R., Maroni, L., Laurenzi, A. & Cescon, M., 2022, I: American Journal of Transplantation. 22, 10, s. 2401-2408

**Impact of MELD 30-allocation policy on liver transplant outcomes in Italy**

Ravaioli, M., Lai, Q., Sessa, M., Ghinolfi, D., Fallani, G., Patrono, D., Di Sandro, S., Avolio, A., Odaldi, F., Bronzoni, J., Tandoi, F., De Carlis, R., Pascale, M. M., Mennini, G., Germinario, G., Rossi, M., Agnes, S., De Carlis, L., Cescon, M., Romagnoli, R. & 1 flere, De Simone, P., 2022, I: Journal of Hepatology. 76, 3, s. 619-627

**Investigation of the potential association between the use of fluoxetine and occurrence of acute pancreatitis: a Danish register-based cohort study**

Aakjær, Mia, Kristiansen, S. B., Pape, K., Sessa, Maurizio, Dalhoff, Kim, De Bruin, M. L. & Andersen, Morten, 2022, I: *International Journal of Epidemiology*. 51, 5, s. 1656–1665

**Pharmacological and epidemiological considerations while constructing treatment episodes using observational data: A simulation study**

Pazzagli, L., Andersen, Morten & Sessa, Maurizio, 2022, I: *Pharmacoepidemiology and Drug Safety*. 31, 1, s. 55-60

**Pharmacom-epi: A framework for integrating pharmacometric modeling into Pharmacoepidemiological research using real-world data**

Soeorg, H., Sverrisdottir, E., Andersen, Morten, Lund, Trine Meldgaard & Sessa, Maurizio, 2022, I: *Pharmacoepidemiology and Drug Safety*. 31, S2, s. 568-569

**Post-marketing safety surveillance of erenumab: new insight from Eudravigilance**

Liang, D. & Sessa, Maurizio, 2022, I: *Expert Opinion on Drug Safety*. 21, 9, s. 1205-1210

**Rationale and performances of a data-driven method for computing the duration of pharmacological prescriptions using secondary data sources**

Pazzagli, L., Liang, D., Andersen, Morten, Linder, M., Khan, A. R. & Sessa, Maurizio, 2022, I: *Scientific Reports*. 12, 1, 8 s., 6245.

**Reply to: "Impact of MELD 30-allocation policy on liver transplant outcomes in Italy: Considerations"**

Sessa, Maurizio, Lai, Q., Germinario, G. & Ravaioli, M., 2022, I: *Journal of Hepatology*. 77, 2, s. 573-574

**Segmental Ureterectomy Versus Radical Nephroureterectomy in Older Patients Treated for Upper Tract Urothelial Carcinoma**

Abrate, A., Sessa, F., Sessa, Maurizio, Campi, R., Sebastianelli, A., Varca, V., Pavone, C., Vella, M., Bartoletti, R., Ficarra, V., Serni, S., Brunocilla, E., Gregori, A., Trombetta, C., Lissiani, A., Terrone, C., Gontero, P., Schiavina, R., Gacci, M. & Simonato, A., 2022, I: *Clinical Genitourinary Cancer*. 20, 4, s. 381-387

**The PHARMACOM-EPI framework for integrating pharmacometric modelling into pharmacoepidemiological research using real-world data: application to assess death associated with valproate**

Soeorg, H., Sverrisdóttir, E., Andersen, Morten, Lund, Trine Meldgaard & Sessa, Maurizio, 2022, I: *Clinical Pharmacology and Therapeutics*. 111, 4, s. 840-856

**The Relationship Between Valproate and Lamotrigine/Levetiracetam Use and Prognosis in Patients With Epilepsy and Heart Failure: A Danish Register-Based Study**

Liang MPharm, D., Gardella, E., Kragholm, K., Polcwiartek, C. & Sessa, Maurizio, 2022, I: *Journal of Cardiac Failure*. 28, 4, s. 630-638

**The Relationship between Timing of Pretransplant Kidney Biopsy, Graft Loss, and Survival in Kidney Transplantation: An Italian Cohort Study**

Odaldi, F., Serenari, M., Comai, G., La Manna, G., Bova, R., Frascaroli, G., Malvi, D., Maroni, L., Vasuri, F., Germinario, G., Baraldi, O., Capelli, I., Cuna, V., Sangiorgi, G., D'Errico, A., Del Gaudio, M., Bertuzzo, V. R., Zanfi, C., Sessa, Maurizio & Ravaioli, M., 2022, I: *Nephron*. 146, 1, s. 22–31

**Artificial Intelligence in Pharmacoepidemiology: A Systematic Review. Part 2–Comparison of the Performance of Artificial Intelligence and Traditional Pharmacoepidemiological Techniques**

Sessa, Maurizio, Liang, D., Khan, A. R., Kulahci, M. & Andersen, Morten, 14 jan. 2021, I: *Frontiers in Pharmacology*. 11, 10 s., 568659.

**A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine**

Pellesi, L., De Icco, R., Alawie, H. Y., Andersen, Morten, Liang, D., Amirgulyiyev, S., Al-Karagholi, M. A., Amin, Faisal Mohammad & Sessa, Maurizio, 2021, I: *Expert Opinion on Drug Safety*. 20, 4, s. 467-474

**Detecting deviations from the efficacy and safety results of single-arm trials using real-world data: The case of a CAR-T cell therapy in B-cell lymphoma**

Jakobsen, L. H., Callréus, T., Sessa, Maurizio, Jerkeman, M., Andersen, Morten & El-Galaly, T. C., 2021, I: *Pharmacoepidemiology and Drug Safety*. 30, 4, s. 514-519

**Incident Atrial Fibrillation and Risk of Psychoactive Drug Redemptions and Psychiatric Hospital Contacts - a Danish Nationwide Register-based Follow-up Study**

Hagengaard, L., Polcwiartek, C., Andersen, M. P., Sessa, Maurizio, Krogager, M. L., Gislason, Gunnar Hilmar, Schou, Morten, Torp-Pedersen, Christian, Søgaaard, P. & Kragholm, K. H., 2021, I: *European Heart Journal - Quality of Care and Clinical Outcomes*. 7, 1, s. 76-82

**Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?**

Ravaioli, M., Piscaglia, F., Cillo, U., Brandi, G., Sessa, Maurizio, Germinario, G., Golfieri, R., Cappelli, A., Morelli, M. C., Siniscalchi, A., D'Errico, A., Cescon, M., Iannone, P. & Trevisani, F., 2021, I: *Liver Cancer*. 10, s. 394–395

**New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database**

Sessa, Maurizio & Andersen, Morten, 2021, I: *BioDrugs*. 35, 2, s. 215-227 13 s.

**Pharmacoepidemiological methods for computing the duration of pharmacological prescriptions using secondary data sources**

Meaidi, M., Støvring, H., Rostgaard, K., Torp-Pedersen, Christian, Kragholm, K. H., Andersen, Morten & Sessa, Maurizio, 2021, I: *European Journal of Clinical Pharmacology*. 77, s. 1805–1814

**Pharmacological and epidemiological considerations while constructing drug treatment episodes using observational data retrospectively collected: A simulation study**

Pazzagli, L., Andersen, Morten & Sessa, Maurizio, 2021, I: *Pharmacoepidemiology and Drug Safety*. 30, S1, s. 298-299

**Sessa empirical estimator (SEE): A data-driven method for predicting the duration of pharmacological prescriptions in secondary data sources**

Sessa, Maurizio, 2021, I: *Pharmacoepidemiology and Drug Safety*. 30, S1, s. 37-37

**The relationship between valproate versus lamotrigine/levetiracetam use and prognosis in patients with epilepsy and heart failure: A Danish register-based study**

Liang, D., Gardella, E., Kragholm, K., Polcwiartek, C. & Sessa, Maurizio, 2021, I: *Pharmacoepidemiology and Drug Safety*. 30, S1, s. 77-78

**Thrombocytopenia after COVID-19 vaccination**

Kragholm, K., Sessa, Maurizio, Mulvad, T., Andersen, M. P., Christensen, Helle Collatz, Blomberg, S. N., Lippert, F., Mikkelsen, S., Leutscher, P., Melgaard, D., Torp-Pedersen, Christian, Kristensen, S. R., Larsen, T. B. & Søgaaard, P., 2021, I: *Journal of Autoimmunity*. 123, 2 s., 102712.

**Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines**

Sessa, Maurizio, Kragholm, K., Hviid, Anders Peter & Andersen, Morten, 2021, I: *Expert Opinion on Drug Safety*. 20, 11, s. 1451-1453

**Metoprolol versus Carvedilol in Patients with Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure**

Sessa, Maurizio, Rasmussen, D. B., Jensen, M. T., Kragholm, K., Torp-pedersen, C. & Andersen, Morten, 1 jan. 2020, I: *The American Journal of Cardiology*. 125, 7, s. 1069-1076

**Angiotensin II and angiotensin 1-7: which is their role in atrial fibrillation?**

Mascolo, A., Urbanek, K., De Angelis, A., Sessa, Maurizio, Scavone, C., Berrino, L., Rosano, G. M. C., Capuano, A. & Rossi, F., 2020, I: *Heart Failure Reviews*. 25, s. 367–380

**Artificial Intelligence in Pharmacoepidemiology: A Systematic Review. Part 1—Overview of Knowledge Discovery Techniques in Artificial Intelligence**

Sessa, Maurizio, Khan, A. R., Liang, D., Andersen, Morten & Kulahci, M., 2020, I: *Frontiers in Pharmacology*. 11, 18 s., 1028.

**Association Between Serum Potassium Levels and Short-Term Mortality in Patients With Atrial Fibrillation or Flutter Co-treated With Diuretics and Rate- or Rhythm-controlling Drugs**

Hagengaard, L., Sogaard, P., Espersen, M., Sessa, Maurizio, Lund, P. E., Krogager, M. L., Torp-Pedersen, Christian, Kragholm, K. H. & Polcwiartek, C., 2020, I: *European heart journal. Cardiovascular pharmacotherapy*. 6, 3, s. 137-144

**Beta-blocker, aspirin and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark**

Rasmussen, D. B., Bodtger, U., Lamberts, Morten Kjøbek, Nicolaisen, S. K., Sessa, Maurizio, Capuano, A., Torp-Pedersen, C., Gislason, Gunnar Hilmar, Lange, Peter & Jensen, M. T., 2020, I: *European Heart Journal - Quality of Care and Clinical Outcomes*. 6, 1, s. 23-31 9 s.

**Predictors of quetiapine extended release formulation Add-On in older patients exposed to antidepressant drugs: A Danish Register-Based cohort study**

Hashimi, H., Andersen, Morten & Sessa, Maurizio, 2020, I: *International Journal of Geriatric Psychiatry*. 35, 10, s. 1156-1162

**Segmental ureterectomy vs. radical nephroureterectomy for ureteral carcinoma in patients with a preoperative glomerular filtration rate less than 90 ml/min/1.73 m<sup>2</sup>: A multicenter study**

Abrate, A., Sessa, F., Campi, R., Preto, M., Olivero, A., Varca, V., Benelli, A., Sessa, M., Sebastianelli, A., Pavone, C., Serretta, V., Vella, M., Brunocilla, E., Serni, S., Trombetta, C., Terrone, C., Gregori, A., Lissiani, A., Gontero, P., Schiavina, R. & 2 flere, Gacci, M. & Simonato, A., 2020, I: *Urologic Oncology: Seminars and Original Investigations*. 38, 6, s. 601.e11-601.e16

**The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine**

Sessa, Maurizio, Mascolo, A., Dalhoff, Kim & Andersen, Morten, 2020, I: *Expert Opinion on Drug Safety*. 19, 3, s. 349-357

**Utilizing drug-target-event relationships to unveil safety patterns in pharmacovigilance**

Hauser, Alexander Sebastian, Kooistra, Albert J., Sverrisdóttir, E. & Sessa, Maurizio, 2020, I: *Expert Opinion on Drug Safety*. 19, s. 961-968

**Hepatitis B Surface Antigen Seropositive Men in Serodiscordant Couples: Effects on the Assisted Reproductive Outcomes**

Cito, G., Coccia, M. E., Fucci, R., Picone, R., Cocci, A., Sessa, Maurizio, Sessa, F., Rizzello, F., Micelli, E., Trotta, M., Badolato, L., Campi, R., Criscuoli, L., Serni, S., Carini, M. & Natali, A., 17 dec. 2019, I: *The world journal of men's health*. 37, 8 s., e63.

**Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study**

Sessa, Maurizio, Mascolo, A., Rasmussen, D. B., Kragholm, K., Jensen, M. T., Sportiello, L., Rafaniello, C., Tari, G. M., Pagliaro, C., Andersen, Morten, Rossi, F. & Capuano, A., 7 aug. 2019, I: *Scientific Reports*. 9, 1, 8 s., 11465.

**Tadalafil 5 mg Alone or in Combination with Tamsulosin 0.4 mg for the Management of Men with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Prospective Observational Trial**

Sebastianelli, A., Spatafora, P., Frizzi, J., Saleh, O., Sessa, Maurizio, De Nunzio, C., Tubaro, A., Vignozzi, L., Maggi, M., Serni, S., McVary, K. T., Kaplan, S. A., Gravas, S., Chapple, C. & Gacci, M., 29 jul. 2019, I: *Journal of Clinical Medicine*. 8, 8

**Intraoperative assessment of ureteral and graft reperfusion during robotic kidney transplantation with indocyanine green fluorescence videography**

Vignolini, G., Sessa, F., Greco, I., Cito, G., Vanacore, D., Cocci, A., Sessa, Maurizio, Grandi, V., Pili, A., Giancane, S., Gacci, M., Sebastianelli, A., Li Marzi, V., Breda, A., Campi, R. & Serni, S., 1 feb. 2019, I: *Minerva Urologica e Nefrologica*.

71, 1, s. 79-84 6 s.

**Montelukast improves symptoms and lung function in asthmatic women compared with men**

Esposito, R., Spaziano, G., Giannattasio, D., Ferrigno, F., Liparulo, A., Rossi, A., Roviezzo, F., Sessa, Maurizio, Falciani, M., Berrino, L., Polverino, M., Polverino, F. & D'Agostino, B., 1 jan. 2019, I: *Frontiers in Pharmacology*. 10, SEP, 9 s., 1094.

**Segmental resection of distal ureter with termino-terminal ureteric anastomosis vs bladder cuff removal and ureteric re-implantation for upper tract urothelial carcinoma: results of a multicentre study**

Abrate, A., Sessa, F., Sebastianelli, A., Preto, M., Olivero, A., Varca, V., Benelli, A., Campi, R., Sessa, M., Pavone, C., Serretta, V., Vella, M., Brunocilla, E., Serni, S., Trombetta, C., Terrone, C., Gregori, A., Lissiani, A., Gontero, P., Schiavina, R. & 2 flere, Gacci, M. & Simonato, A., 1 jan. 2019, I: *BJU International*. 124, 1, s. 116-123

**Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase®**

Sessa, Maurizio, Mascolo, A., Callréus, T., Capuano, A., Rossi, F. & Andersen, Morten, 2019, I: *Scientific Reports*. 9, 1, 8 s., 7236.

**Monitoring of medicinal products authorized based on a single-arm trial: The case of a CAR-T cell therapy**

Callreus, T., Sessa, Maurizio, El-Galaly, T., Jerkeman, M. & Andersen, Morten, 2019, s. 190-190.

**Montelukast induces better control of symptoms and management of lung function, and decreased inflammation in women compared with men**

Spaziano, G., Polverino, F., Giannattasio, D., Ferrigno, F., Sessa, Maurizio, Rossi, A., Roviezzo, F., Polverino, M. & D'Agostino, B., 2019, s. PA2535. 1 s.

**Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System**

Mascolo, A., Ruggiero, R., Sessa, Maurizio, Scavone, C., Sportiello, L., Rafaniello, C., Rossi, F. & Capuano, A., 2019, I: *Frontiers in Pharmacology*. 10, 12 s., 425.

**Robot-assisted nephron-sparing surgery for cystic nephroma in a pediatric patient: A case report**

Masieri, L., Sessa, F., Cini, C., Sessa, Maurizio, Vanacore, D., Tasso, G., Pili, A., Sforza, S., Greco, I., Campi, R., Minervini, A. & Carini, M., 2019, I: *Journal of Endourology Case Reports*. 5, 1, s. 7-9 3 s.

**Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study**

Scavone, C., Sessa, Maurizio, Clementi, E., Corrao, G., Leone, R., Mugelli, A., Rossi, F., Spina, E. & Capuano, A., 1 dec. 2018, I: *BioDrugs*. 32, 6, s. 607-617 11 s.

**Photodynamic therapy with topical photosensitizers in mucosal and semimucosal areas: review from a dermatologic perspective**

Grandi, V., Sessa, Maurizio, Pisano, L., Rossi, R., Galvan, A., Gattai, R., Mori, M., Tiradritti, L., Bacci, S., Zuccati, G., Cappugi, P. & Pimpinelli, N., sep. 2018, I: *Photodiagnosis and Photodynamic Therapy*.

**Contribution of Italian clinical research for contrast media-induced nonrenal adverse drug reactions over the last three decades: A systematic review**

Sessa, Maurizio, Rossi, C., Mascolo, A., Scafuro, A., Ruggiero, R., Di Mauro, G., Cappabianca, S., Grassi, R., Sportiello, L. & Rafaniello, C., 1 jul. 2018, I: *Journal of Pharmacology and Pharmacotherapeutics*. 9, 3, s. 131-146 16 s.

**The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions**

Rafaniello, C., Sessa, Maurizio, Bernardi, F. F., Pozzi, M., Cheli, S., Cattaneo, D., Baldelli, S., Molteni, M., Bernardini, R., Rossi, F., Clementi, E., Bravaccio, C., Radice, S. & Capuano, A., 22 maj 2018, I: *Pharmacogenomics Journal*. 18, 3, s. 422-430 9 s.

**Preventable statin adverse reactions and therapy discontinuation. What can we learn from the spontaneous reporting system?**

Sessa, Maurizio, Rafaniello, C., Scavone, C., Mascolo, A., di Mauro, G., Fucile, A., Rossi, F., Sportiello, L. & Capuano, A., 4 maj 2018, I: *Expert Opinion on Drug Safety*. 17, 5, s. 457–465

**ALA-PDT exerts beneficial effects on chronic venous ulcers by inducing changes in inflammatory microenvironment, especially through increased TGF-beta release: A pilot clinical and translational study.**

Grandi, V., Bacci, S., Corsi, A., Sessa, Maurizio, Puliti, E., Murciano, N., Scavone, F., Cappugi, P. & Pimpinelli, N., mar. 2018, I: *Photodiagnosis and Photodynamic Therapy*. 21, s. 252-256 5 s.

**Predictors of new oral anticoagulant drug initiation as opposed to warfarin in elderly adults: A retrospective observational study in Southern Italy**

Guerriero, F., Orlando, V., Monetti, V. M., Colaccio, F. M., Sessa, Maurizio, Scavone, C., Capuano, A. & Menditto, E., 1 jan. 2018, I: *Therapeutics and Clinical Risk Management*. 14, s. 1907-1914 8 s.

**Adverse drug reactions during hepatitis C treatment with direct-acting antivirals: The role of medication errors, their impact on treatment discontinuation and their preventability. New insights from the Campania Region (Italy) spontaneous reporting system**

Sessa, Maurizio, Bernardi, F. F., Vitale, A., Schiavone, B., Gritti, G., Mascolo, A., Bertini, M., Scavone, C., Sportiello, L., Rossi, F. & Capuano, A., 2018, I: *Journal of Clinical Pharmacy and Therapeutics*. 43, 6, s. 867-876

**Comparison of long-term clinical implications of beta-blockade in patients with obstructive airway diseases exposed to beta-blockers with different  $\beta$ 1-adrenoreceptor selectivity: An Italian population-based cohort study**

Sessa, Maurizio, Mascolo, A., Scavone, C., Perone, I., Giorgio, A. D., Tari, M., Fucile, A., De Angelis, A., Rasmussen, D. B., Jensen, M. T., Kragholm, K., Rossi, F., Capuano, A. & Sportiello, L., 2018, I: *Frontiers in Pharmacology*. 9, s. 1-8 1212.

**Efficacy and safety of S-acyl glutathione 2% cream vs. placebo against UVB-induced erythema: a randomized, double-blinded clinical trial**

Grandi, V., Milanese, N., Sessa, Maurizio, Gola, M., Cappugi, P. & Pimpinelli, N., 2018, (E-pub ahead of print) I: *Giornale Italiano di Dermatologia e Venereologia*.

**Italian Immunization Goals: A Political or Scientific Heated Debate?**

Scavone, C., Sessa, Maurizio, Clementi, E., Rossi, F. & Capuano, A., 2018, I: *Frontiers in Pharmacology*. 9, s. 574

**Pillars and Pitfalls of the New Pharmacovigilance Legislation: Consequences for the Identification of Adverse Drug Reactions Deriving From Abuse, Misuse, Overdose, Occupational Exposure, and Medication Errors**

Sessa, Maurizio, di Mauro, G., Mascolo, A., Rafaniello, C., Sportiello, L., Scavone, C. & Capuano, A., 2018, I: *Frontiers in Pharmacology*. 9, 10 s.

**Relationship between gender and the effectiveness of montelukast: An Italian/Danish register-based retrospective cohort study**

Sessa, Maurizio, Mascolo, A., D'Agostino, B., Casciotta, A., D'Agostino, V., De Michele, F., Polverino, M., Spaziano, G., Andersen, M. P., Kragholm, K., Rossi, F., Torp-Pedersen, C. & Capuano, A., 2018, I: *Frontiers in Pharmacology*. 9, s. 1-12 12 s., 844.

**Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: A Danish nationwide cohort study**

Sessa, Maurizio, Mascolo, A., Mortensen, R. N., Andersen, M. P., Rosano, G. M. C., Capuano, A., Rossi, F., Gislason, Gunnar Hilmar, Poulsen, Henrik Enghusen & Torp-Pedersen, C., 2018, I: *European Journal of Heart Failure*. 20, 3, s. 548-556

**Contrast media-induced nephropathy: how has Italy contributed in the past 30 years? A systematic review**

Sessa, Maurizio, Rossi, C., Mascolo, A., Scavone, C., di Mauro, G., Grassi, R., Sportiello, L., Cappabianca, S. & Rafaniello, C., okt. 2017, I: *Therapeutics and Clinical Risk Management*. 13, s. 1463-1478 16 s.



**Safety profile of anticancer and immune-modulating biotech drugs used in a real world setting in Campania Region (Italy): BIO-Cam observational study**  
Scavone, C., Sportiello, L., Sullo, M. G., Ferrajolo, C., Ruggiero, R., Sessa, Maurizio, Berrino, P. M., di Mauro, G., Berrino, L., Rossi, F., Rafaniello, C., Capuano, A. & BIO-Cam Group, B. G., 6 sep. 2017, I: *Frontiers in Pharmacology*. 8, 14 s., 607.

**New and old roles of the peripheral and brain renin–angiotensin–aldosterone system (RAAS): Focus on cardiovascular and neurological diseases**  
Mascolo, A., Sessa, Maurizio, Scavone, C., De Angelis, A., Vitale, C., Berrino, L., Rossi, F., Rosano, G. & Capuano, A., 15 jan. 2017, I: *International Journal of Cardiology*. 227, s. 734-742 9 s.

**Anatomical templates of lymph node dissection for upper tract urothelial carcinoma: a systematic review of the literature**  
Campi, R., Minervini, A., Mari, A., Hatzichristodoulou, G., Sessa, F., Lapini, A., Sessa, Maurizio, Gschwend, J. E., Serni, S., Roscigno, M. & Carini, M., 2017, I: *Expert Review of Anticancer Therapy*. 17, 3, s. 235-246

**Campania Preventability Assessment Committee (Italy): A Focus on the Preventability of Non-steroidal Anti-inflammatory Drugs' Adverse Drug Reactions**  
Sessa, Maurizio, Sportiello, L., Mascolo, A., Scavone, C., Gallipoli, S., di Mauro, G., Cimmaruta, D., Rafaniello, C. & Capuano, A., 2017, I: *Frontiers in Pharmacology*. 8, s. 305 10 s.

**Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting**  
Mascolo, A., Scavone, C., Sessa, Maurizio, di Mauro, G., Cimmaruta, D., Orlando, V., Rossi, F., Sportiello, L. & Capuano, A., 2017, I: *Pharmacological Research*. 123, s. 122-129

**Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease**  
Pileri, S. A., Agostinelli, C., Sessa, Maurizio, Quaglino, P., Santucci, M., Tomasini, C., Grandi, V., Fava, P., Astrua, C., Righi, S., Patrizi, A., Pileri, S. A. & Pimpinelli, N., 2017, I: *Virchows Archiv*. 470, 5, s. 575–582

**Positive surgical margins and local recurrence after simple enucleation and standard partial nephrectomy for malignant renal tumors: systematic review of the literature and meta-analysis of prevalence**  
Minervini, A., Campi, R., Sessa, F., Derweesh, I., Kaouk, J. H., Mari, A., Rha, K. H., Sessa, Maurizio, Volpe, A., Carini, M. & Uzzo, R. G., 2017, I: *Minerva Urologica e Nefrologica*. 69, 6, s. 523-538 16 s.

**Campania Region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs.**  
Sessa, Maurizio, Rafaniello, C., Sportiello, L., Mascolo, A., Scavone, C., Maccariello, A., Iannaccone, T., Fabrazzo, M., Berrino, L., Rossi, F. & Capuano, A., dec. 2016, I: *Expert Opinion on Drug Safety*. 15, sup2, s. 9-15 7 s.

**Campania preventability assessment committee: a focus on the preventability of the contrast media adverse drug reactions.**  
Sessa, Maurizio, Rossi, C., Rafaniello, C., Mascolo, A., Cimmaruta, D., Scavone, C., Fiorentino, S., Grassi, E., Reginelli, A., Rotondo, A. & Sportiello, L., dec. 2016, I: *Expert Opinion on Drug Safety*. 15, sup2, s. 51-59 9 s.

**Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases**  
Mascolo, A., Rafaniello, C., Sportiello, L., Sessa, Maurizio, Cimmaruta, D., Rossi, F. & Capuano, A., feb. 2016, I: *Drug Safety*. 39, 5, s. 401-407

**Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system.**  
Rafaniello, C., Ferrajolo, C., Sullo, M. G., Sessa, Maurizio, Sportiello, L., Balzano, A., Manguso, F., Aiezza, M. L., Rossi, F., Scarpignato, C. & Capuano, A., feb. 2016, I: *Pharmacological Research*. 104, s. 108-114 7 s.

**A case of figurate urticaria by etanercept.**  
Sessa, Maurizio, Sullo, M. G., Mascolo, A., Cimmaruta, D., Romano, F., Puca, R. V., Capuano, A., Rossi, F. & Schiavo, A. L., 2016, I: *Journal of Pharmacology and Pharmacotherapeutics*. 7, 2, s. 106-108 3 s.

**Effect of Chronic Kidney Diseases on Mortality among Digoxin Users Treated for Non-Valvular Atrial Fibrillation: A Nationwide Register-Based Retrospective Cohort Study**

Sessa, Maurizio, Mascolo, A., Andersen, M. P., Rosano, G., Rossi, F., Capuano, A. & Torp-Pedersen, C., 2016, I: PLoS ONE. 11, 7, 19 s., e0160337.

**New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs)**

Scavone, C., Sportiello, L., Rafaniello, C., Mascolo, A., Sessa, Maurizio, Rossi, F. & Capuano, A., 2016, I: Expert Opinion on Drug Safety. S2, S2, s. 85-100 16 s.

**Suspected adverse reactions to contrast media in Campania Region (Italy): results from 14 years of post-marketing surveillance.**

Sessa, Maurizio, Rossi, C., Mascolo, A., Grassi, E., Fiorentino, S., Scavone, C., Reginelli, A., Rotondo, A. & Sportiello, L., jan. 2015, I: Expert Opinion on Drug Safety. 14, 9, s. 1341-1351 11 s.

**Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy.**

Parretta, E., Rafaniello, C., Magro, L., Coggiola Pittoni, A., Sportiello, L., Ferrajolo, C., Mascolo, A., Sessa, Maurizio, Rossi, F. & Capuano, A., sep. 2014, I: Expert Opinion on Drug Safety. 13 Suppl 1, s. S21-9